Literature DB >> 24830941

Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping.

Ngome L Makia1, Sailesh Surapureddi1, Katalin Monostory1, Russell A Prough1, Joyce A Goldstein2.   

Abstract

Cytochrome P450 (CYP)2C9 and CYP2C19 are important human enzymes that metabolize therapeutic drugs, environmental chemicals, and physiologically important endogenous compounds. Initial studies using primary human hepatocytes showed induction of both the CYP2C9 and CYP2C19 genes by tert-butylhydroquinone (tBHQ). As a pro-oxidant, tBHQ regulates the expression of cytoprotective genes by activation of redox-sensing transcription factors, such as the nuclear factor E2-related factor 2 (Nrf2) and members of the activator protein 1 (AP-1) family of proteins. The promoter region of CYP2C9 contains two putative AP-1 sites (TGAGTCA) at positions -2201 and -1930, which are also highly conserved in CYP2C19. The CYP2C9 promoter is activated by ectopic expression of cFos and JunD, whereas Nrf2 had no effect. Using specific kinase inhibitors for mitogen-activated protein kinase, we showed that extracellular signal-regulated kinase and Jun N-terminal kinase are essential for tBHQ-induced expression of CYP2C9. Electrophoretic mobility shift assays demonstrate that cFos distinctly interacts with the distal AP-1 site and JunD with the proximal site. Because cFos regulates target genes as heterodimers with Jun proteins, we hypothesized that DNA looping might be required to bring the distal and proximal AP-1 sites together to activate the CYP2C9 promoter. Chromosome conformation capture analyses confirmed the formation of a DNA loop in the CYP2C9 promoter, possibly allowing interaction between cFos at the distal site and JunD at the proximal site to activate CYP2C9 transcription in response to electrophiles. These results indicate that oxidative stress generated by exposure to electrophilic xenobiotics and metabolites induces the expression of CYP2C9 and CYP2C19 in human hepatocytes. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24830941      PMCID: PMC4127925          DOI: 10.1124/mol.114.092585

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  50 in total

1.  Quantitative analysis of chromosome conformation capture assays (3C-qPCR).

Authors:  Hélène Hagège; Petra Klous; Caroline Braem; Erik Splinter; Job Dekker; Guy Cathala; Wouter de Laat; Thierry Forné
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

2.  The role of heterodimeric AP-1 protein comprised of JunD and c-Fos proteins in hematopoiesis.

Authors:  Sung-Young Lee; Jaeho Yoon; Mee-Hyun Lee; Sung Keun Jung; Dong Joon Kim; Ann M Bode; Jaebong Kim; Zigang Dong
Journal:  J Biol Chem       Date:  2012-07-20       Impact factor: 5.157

3.  c-Jun NH(2)-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor.

Authors:  Juan-Jose Ventura; Norman J Kennedy; Jennifer A Lamb; Richard A Flavell; Roger J Davis
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

Review 4.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 5.  Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology.

Authors:  John Cl Erve
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

6.  Cytochrome P450 2C is an EDHF synthase in coronary arteries.

Authors:  B Fisslthaler; R Popp; L Kiss; M Potente; D R Harder; I Fleming; R Busse
Journal:  Nature       Date:  1999-09-30       Impact factor: 49.962

Review 7.  Investigation of the CYP2C9 induction profile in human hepatocytes by combining experimental and modelling approaches.

Authors:  Ales Belic; Manna Temesvári; Krisztina Kohalmy; Radim Vrzal; Zdenek Dvorak; Damjana Rozman; Katalin Monostory
Journal:  Curr Drug Metab       Date:  2009-12       Impact factor: 3.731

8.  Influence of rifampicin and isoniazid on the kinetics of phenytoin.

Authors:  L Kay; J P Kampmann; T L Svendsen; B Vergman; J E Hansen; L Skovsted; M Kristensen
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

9.  The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter.

Authors:  Yuping Chen; Grace Kissling; Masahiko Negishi; Joyce A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2005-05-26       Impact factor: 4.030

Review 10.  Biochemistry and molecular biology of the human CYP2C subfamily.

Authors:  J A Goldstein; S M de Morais
Journal:  Pharmacogenetics       Date:  1994-12
View more
  5 in total

1.  CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver.

Authors:  Ngome L Makia; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2015-10-14       Impact factor: 4.436

2.  Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin.

Authors:  Nunzia Pastore; Sergio Attanasio; Barbara Granese; Raffaele Castello; Jeffrey Teckman; Andrew A Wilson; Andrea Ballabio; Nicola Brunetti-Pierri
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

3.  The gene expression profile of a drug metabolism system and signal transduction pathways in the liver of mice treated with tert-butylhydroquinone or 3-(3'-tert-butyl-4'-hydroxyphenyl)propylthiosulfonate of sodium.

Authors:  Alexandra B Shintyapina; Valentin A Vavilin; Olga G Safronova; Vyacheslav V Lyakhovich
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

4.  Influence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.

Authors:  Yu Wang; Xiao-Dong Yi; Hai-Lin Lu
Journal:  Med Sci Monit       Date:  2017-04-12

5.  Binding of a Smad4/Ets-1 complex to a novel intragenic regulatory element in exon12 of FPGS underlies decreased gene expression and antifolate resistance in leukemia.

Authors:  Shachar Raz; Michal Stark; Yehuda G Assaraf
Journal:  Oncotarget       Date:  2014-10-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.